Indivior PLC Ordinary Shares

$12.43
(as of Jun 3, 9:33 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Indivior PLC Ordinary Shares

Stock Price
$12.43
Ticker Symbol
INDV
Exchange
NASDAQ

Industry Information for Indivior PLC Ordinary Shares

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Indivior PLC Ordinary Shares

Website
https://www.indivior.com
Country
USA
Full Time Employees
1,030

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Fundamentals for Indivior PLC Ordinary Shares

Market Capitalization
$1,590,543,872
EBITDA
$309,000,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.05
Earnings per Share Estimate Next Year
Profit Margin
-5.30%
Shares Outstanding
124,770,000
Percent Owned by Insiders
4.01%
Percent Owned by Institutions
87.61%
52-Week High
52-Week Low

Technical Indicators for Indivior PLC Ordinary Shares

50-Day Moving Average
200-Day Moving Average
RSI
74.01
ATR
0.52

Analyst Ratings for Indivior PLC Ordinary Shares

Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0

News About Indivior PLC Ordinary Shares

Jun 2, 2025, 5:24 AM EST
A £1.1bn drug company is to quit the London Stock Exchange as the troubled market battles an exodus of businesses. See more.
Jun 2, 2025, 4:18 AM EST
[4K conveyor with moving empty white plastic tubes on the production line and filling with capsules. See more.
Jun 2, 2025, 2:33 AM EST
(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. See more.
Jun 2, 2025, 2:33 AM EST
(Reuters) -Pharma firm Indivior said on Monday it would cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. See more.